Opens in a new tab

Breaking news

Volkswagen’s Cost-Cutting Plan Faces Scrutiny As Traditional Methods Clash with Bold Promises

Volkswagen’s recent cost-cutting agreement, hailed as crucial for its survival amidst increasing competition and declining demand, leans heavily on the company’s longstanding tradition of collaboration between management and workers. However, this approach has sparked concerns among investors about the company’s ability to meet its ambitious targets, including reducing capacity and cutting 35,000 jobs.

The deal, which was reached just before Christmas, aims to tackle the company’s challenges, with workers and unions now engaging in discussions at factories across Germany to clarify the details. According to company sources, each plant will be given its cost-reduction target, with mixed teams of managers and labor representatives working together to devise strategies that enhance productivity. These targets will be reviewed quarterly, and if any interim milestones are missed, new negotiations may be necessary.

This method aligns with Volkswagen’s history of compromise and cooperation, but it also raises questions about its effectiveness in driving the required changes. The model avoids a top-down restructuring approach that might have been more decisive but could have led to unrest or strikes.

Investors have been left underwhelmed by the deal, with Volkswagen shares trading below the levels seen in October, before a sharp decline in quarterly profits. Analysts like Patrick Hummel from UBS believe the market needs to see concrete plans for long-term profitability, with a focus on how the cost-cutting measures will impact the company’s bottom line in the next two years.

Capacity Reductions And Plant Closures Remain Uncertain

As the deal progresses, questions persist about how Volkswagen will reduce its workforce and production capacity. Unions have been informed that the company is considering closing three to four plants, though Volkswagen has declined to confirm specific closures. The final agreement does include the closure of two factories: one in Dresden by 2025, and another in Osnabrueck by 2027. However, both sites may be repurposed for alternative uses, with potential new investors involved.

The company’s Zwickau plant, which produces electric vehicles, will lose one production line but will receive investment in a new recycling facility, which is set to begin operations in 2027. These new investments, however, are contingent on meeting cost-cutting goals, as Volkswagen’s finance chief Arno Antlitz made clear in recent comments to investors.

The company has also identified capacity reductions at its Wolfsburg headquarters, where two production lines will be cut. While Volkswagen has stated that the deal will result in savings of €15 billion over the “medium term,” investors remain uncertain about how this approach compares to the more direct route of plant closures.

Job Cuts Remain A Major Challenge

Another pressing concern is how Volkswagen will achieve its target of shedding 35,000 jobs. While the company previously promised to cut 30,000 jobs in 2016, its workforce size has remained largely stable due to new hires in other areas. The current plan to meet the target relies on not replacing retiring employees and offering voluntary early or partial retirement options. A clause in the deal guarantees jobs until 2030, a concession won by unions after Volkswagen canceled a previous job guarantee agreement in September.

Despite the uncertainties surrounding the cost-cutting plan, some analysts believe that Volkswagen’s CEO, Oliver Blume, has done well in navigating the complexities of dealing with unions and local politicians, who have significant influence over the company’s decisions. Moritz Kronenberger, portfolio manager at Union Investment, notes that although the deal may appear underwhelming, it represents deeper cuts than many had anticipated.

Blume’s leadership is under scrutiny. As Kronenberger points out, “Blume remains the right CEO, but the company’s cost structure must look very different in two years. Volkswagen needs to prove it’s ready for the future and can continue to produce attractive products.” For now, Blume’s ambitious promises have left him both vulnerable and accountable as Volkswagen seeks to secure its future in a rapidly changing industry.

Blood Proteins May Signal Prostate Cancer Risk More Than 15 Years Before Diagnosis

Distinctive proteins in men’s blood may offer clues to prostate cancer risk more than 15 years before a diagnosis, according to research from the University of Oxford. The findings could help scientists better understand why some prostate cancers become aggressive while others grow slowly and never cause serious harm.

Researchers analyzed blood samples from 2,555 men collected between 1992 and 2000. Of those participants, 982 were later diagnosed with prostate cancer; the remaining 1,573 served as a comparison group. The team measured more than 6,000 proteins in the samples, which had been collected years—and, in some cases, more than 15 years—before diagnosis.

Protein Patterns Were Linked To Different Risks

The analysis identified proteins associated with prostate cancer risk overall, as well as proteins linked specifically to more aggressive or fast-growing forms of the disease. Higher levels of certain immune-system proteins, including GZMK and ANXA2, were associated with a lower long-term risk.

“Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease,” said Karl Smith-Byrne, the study’s corresponding author at Oxford.

The results, published in European Urology, are significant because prostate cancer is not a single, uniform disease. Many tumors grow slowly and may never threaten a patient’s health, while others progress rapidly and can be life-threatening. A clearer way to distinguish between these outcomes could eventually help improve how clinicians assess risk.

Promising Findings, Not A Screening Test

The researchers stressed that the protein patterns are not ready to be used as a screening test. The associations need further validation before they can inform clinical decisions, and the study does not establish that the proteins cause cancer or that measuring them can predict an individual’s outcome.

“Ultimately, we hope this will help us understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future,” said first author Zhe Huang, a postdoctoral epidemiologist at Oxford Population Health.

Research Could Point To New Prevention Strategies

Prostate cancer is the most commonly diagnosed cancer among men in the European Union and the second most common worldwide, after lung cancer. In the EU, approximately 330,000 cases are diagnosed and 75,000 men die from the disease each year.

By identifying biological signals that appear long before diagnosis, the research may help scientists investigate the pathways involved in aggressive disease. Smith-Byrne said that, alongside existing and future genetic evidence, the findings could help reveal pathways that might ultimately be targeted to prevent aggressive prostate cancer.

Uol
Aretilaw firm
The Future Forbes Realty Global Properties
eCredo

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter